Form D · Pharmaceuticals
Celeris Therapeutics, Inc.
Graz, C4 · CIK 0001913452
Offering snapshot reported Feb 24, 2022 · SEC filing
- Reported sold
- $2.96M Offering amount: $4.71M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 9, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2022 | Initial | $2,955,243 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-434920
The total amount remaining to be sold will be to the current purchasers if certain triggering events occur pursuant to warrants.
Source: Form D, filed Feb 24, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jakob Ferdinand Hohenberger | Director, Executive |
| Karel Kubias | Director |
| Petr Sramek | Director |
| Marius Swart | Director |
| Christopher Trummer | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Ledermoarweg 25/6
Graz, C4, 8010
Graz, C4, 8010